Tigecycline-Containing Regimens and Multi Drug-Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis

替加环素 医学 内科学 鲍曼不动杆菌 荟萃分析 观察研究 置信区间 不动杆菌 系统回顾 梅德林 抗生素 微生物学 生物 铜绿假单胞菌 遗传学 细菌 生物化学
作者
Fatemeh Sodeifian,Moein Zangiabadian,Erfan Arabpour,Naghmeh Kian,Fartous Yazarlou,Mehdi Goudarzi,Rosella Centis,Zahra Sadat Seghatoleslami,Mahdis Chahar Kameh,Bardia Danaei,Hossein Goudarzi,Mohammad Javad Nasiri,Giovanni Sotgiu,Giovanni Battista Migliori
出处
期刊:Microbial Drug Resistance [Mary Ann Liebert, Inc.]
卷期号:29 (8): 344-359 被引量:7
标识
DOI:10.1089/mdr.2022.0248
摘要

Introduction: The use of tigecycline (TG) for the treatment of Acinetobacter baumannii is controversial. In this systematic review and meta-analysis, we aimed to better explore the safety and efficacy of TG for the treatment of multi drug-resistant (MDR) Acinetobacter. Methods: We searched PubMed/MEDLINE, Scopus, Cochrane Central, and Web of Science to identify studies reporting the clinical and microbiological efficacy and safety of regimens containing TG in patients with drug susceptibility testing (DST)-confirmed MDR A. baumannii, published until December 30, 2022. Observational studies were included if they reported clinical and microbiological efficacy of TG-based regimens. The Newcastle-Ottawa Scale (NOS) and Joana Briggs Institute (JBI) critical appraisal tool were used to assess the quality of included studies. Results: There were 30 observational studies, of which 19 studies were cohort and 11 studies were single group studies. Pooled clinical response and failure rates in the TG-containing regimens group were 58.1 (95% confidence interval [CI] 49.2-66.6) and 40.2 (95% CI 31.1-50.0), respectively. The pooled microbiological response rate was 32.1 (95% CI 19.8-47.5), and the pooled all-cause mortality rate was 41.1 (95% CI 34.1-48.4). Pooled clinical response and failure rates in the colistin-based regimens group were 52.7 (42.7-62.5) and 43.1 (33.1-53.8), respectively. The pooled microbiological response rate was 42.9 (16.2-74.5), and the pooled all-cause mortality rate was 34.3 (26.1-43.5). Conclusions: According to our results, the efficacy of the TG-based regimen is the same as other antibiotics. However, our study showed a high mortality rate and a lower rate of microbiological eradication for TG compared with colistin-based regimen. Therefore, our study does not recommend it for the treatment of MDR A. baumannii. However, this was a prevalence meta-analysis of observational studies, and for better conclusion experimental studies are required.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
boss完成签到,获得积分10
3秒前
无限的千凝完成签到 ,获得积分10
4秒前
科研通AI5应助顺心柠檬采纳,获得10
5秒前
科研通AI5应助贺小刚采纳,获得10
6秒前
7秒前
毛毛虫发布了新的文献求助10
8秒前
jor666完成签到,获得积分10
9秒前
10秒前
zero灬给leolin的求助进行了留言
11秒前
Arthur完成签到 ,获得积分10
12秒前
13秒前
迅速云朵发布了新的文献求助10
14秒前
通不通la发布了新的文献求助10
15秒前
16秒前
AlwaysKim发布了新的文献求助10
20秒前
啊哈哈哈哈完成签到,获得积分10
23秒前
23秒前
我是老大应助NeuroYan采纳,获得50
24秒前
AlwaysKim完成签到,获得积分10
27秒前
sszz发布了新的文献求助10
28秒前
科研通AI5应助科研通管家采纳,获得10
31秒前
传奇3应助科研通管家采纳,获得10
31秒前
pluto应助科研通管家采纳,获得20
32秒前
科研通AI5应助AlwaysKim采纳,获得30
35秒前
靓丽的战斗机完成签到,获得积分10
36秒前
碧蓝的盼夏完成签到,获得积分10
38秒前
40秒前
生动的书蕾完成签到,获得积分10
41秒前
xRuri发布了新的文献求助10
43秒前
小杰完成签到 ,获得积分10
44秒前
45秒前
45秒前
情怀应助迅速云朵采纳,获得10
47秒前
开坦克的贝塔完成签到,获得积分10
48秒前
yuan发布了新的文献求助10
49秒前
50秒前
风趣秋白完成签到,获得积分10
53秒前
研友_8Y2DXL完成签到,获得积分10
53秒前
yoyo20012623发布了新的文献求助30
55秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Les Mantodea de Guyane Insecta, Polyneoptera 2500
Technologies supporting mass customization of apparel: A pilot project 450
Brain and Heart The Triumphs and Struggles of a Pediatric Neurosurgeon 400
Cybersecurity Blueprint – Transitioning to Tech 400
Mixing the elements of mass customisation 400
Периодизация спортивной тренировки. Общая теория и её практическое применение 310
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3783164
求助须知:如何正确求助?哪些是违规求助? 3328499
关于积分的说明 10236697
捐赠科研通 3043596
什么是DOI,文献DOI怎么找? 1670599
邀请新用户注册赠送积分活动 799766
科研通“疑难数据库(出版商)”最低求助积分说明 759119